ANDA 76869, held by Actavis Labs Fl Inc. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76869 (Metformin Hydrochloride), held by Actavis Labs Fl Inc, was first approved by FDA on Apr 12, 2005, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 12, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 29Labeling · Standard review | Approved | None posted |
| Feb 26, 2019 | Supplement 24Labeling · Standard review | Approved | None posted |
| Feb 26, 2019 | Supplement 26Labeling · Standard review | Approved | None posted |
| Oct 31, 2008 | Supplement 11Labeling | Approved | None posted |
| May 25, 2007 | Supplement 4Labeling | Approved | None posted |
| Apr 12, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters